Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. decreased its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,101 shares of the company’s stock after selling 31,298 shares during the period. Platinum Investment Management Ltd. owned 0.12% of Centessa Pharmaceuticals worth $3,879,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Foresite Capital Management VI LLC increased its position in Centessa Pharmaceuticals by 4.8% during the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock worth $31,865,000 after buying an additional 60,640 shares during the period. Eagle Health Investments LP acquired a new position in Centessa Pharmaceuticals during the third quarter worth approximately $2,500,000. Royce & Associates LP acquired a new position in Centessa Pharmaceuticals during the third quarter worth approximately $5,999,000. SG Americas Securities LLC increased its position in Centessa Pharmaceuticals by 1,017.7% during the fourth quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock worth $6,593,000 after buying an additional 240,039 shares during the period. Finally, Cinctive Capital Management LP acquired a new position in Centessa Pharmaceuticals during the third quarter worth approximately $2,246,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on CNTA shares. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Wells Fargo & Company lowered Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Finally, B. Riley Financial lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Trading Down 0.1%

NASDAQ:CNTA opened at $39.72 on Friday. The firm has a market cap of $5.93 billion, a P/E ratio of -22.19 and a beta of 1.11. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The stock’s 50 day simple moving average is $39.64 and its 200-day simple moving average is $30.87. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $11.77 and a 12-month high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Insider Activity

In other news, insider Karen M. Anderson sold 64,768 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.21, for a total value of $1,827,105.28. Following the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,751,417.85. The trade was a 51.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 115,887 shares of company stock valued at $3,346,523 over the last quarter. Insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.